Clinical and Laboratory Parameters of GonadotropinReleasing Hormone Analog Treatment Effectiveness in Children with Precocious Puberty

Detalhes bibliográficos
Autor(a) principal: Fujita, Lívia Grimaldi Abud
Data de Publicação: 2019
Outros Autores: Palhares, Heloísa Marcelina da Cunha, Silva, Adriana Paula da, Tomé, Janaíne Machado, Borges, Maria de Fátima
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/164113
Resumo: OBJECTIVE: There are no doubts about the clinical benefits of treatment with GnRH analogs for patients diagnosed with central precocious puberty (CPP). However, laboratory monitoring of CPP is still a matter of considerable controversy in the literature. Therefore, the main objective of this study was to evaluate the cut-off values of stimulated LH that determine gonadotrophic suppression. METHODS: Twenty-four girls, on treatment with leuprorelin acetate (LA) at 3.75 mg IM every 28 days, were studied. The clinical parameters used to indicate clinical effectiveness were regression or maintenance of sexual characteristics according to the Tanner stage, growth velocity reduction, reduction or maintenance of the difference between bone age and chronological age and maintenance or improvement of the final height prediction. For the laboratory effectiveness test, basal estradiol, LH, and FSH levels were collected before and 1 and 2 h after the administration of 3.75 mg LA. RESULTS: Eleven girls showed improvement in all clinical parameters, and their effectiveness tests were compared to those of the other patients to calculate the cut-off values, which were p3.64 IU/L (p=0.004*) for LH after 1 h and p6.10 IU/L (po0.001*) for LH after 2 h. CONCLUSION: The LH response after the LA stimulation test, associated with clinical data and within a context of CPP, constitutes a reliable and feasible resource and can assist in monitoring the effectiveness of treatment.
id USP-19_e5174cdded90dfe46b60be23deff47ee
oai_identifier_str oai:revistas.usp.br:article/164113
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Clinical and Laboratory Parameters of GonadotropinReleasing Hormone Analog Treatment Effectiveness in Children with Precocious PubertyGonadotropin-Releasing HormonePubertyTherapeuticsLuteinizing HormoneFollicle Stimulating HormoneEstradiolGrowthOBJECTIVE: There are no doubts about the clinical benefits of treatment with GnRH analogs for patients diagnosed with central precocious puberty (CPP). However, laboratory monitoring of CPP is still a matter of considerable controversy in the literature. Therefore, the main objective of this study was to evaluate the cut-off values of stimulated LH that determine gonadotrophic suppression. METHODS: Twenty-four girls, on treatment with leuprorelin acetate (LA) at 3.75 mg IM every 28 days, were studied. The clinical parameters used to indicate clinical effectiveness were regression or maintenance of sexual characteristics according to the Tanner stage, growth velocity reduction, reduction or maintenance of the difference between bone age and chronological age and maintenance or improvement of the final height prediction. For the laboratory effectiveness test, basal estradiol, LH, and FSH levels were collected before and 1 and 2 h after the administration of 3.75 mg LA. RESULTS: Eleven girls showed improvement in all clinical parameters, and their effectiveness tests were compared to those of the other patients to calculate the cut-off values, which were p3.64 IU/L (p=0.004*) for LH after 1 h and p6.10 IU/L (po0.001*) for LH after 2 h. CONCLUSION: The LH response after the LA stimulation test, associated with clinical data and within a context of CPP, constitutes a reliable and feasible resource and can assist in monitoring the effectiveness of treatment.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2019-11-14info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/xmlhttps://www.revistas.usp.br/clinics/article/view/16411310.6061/clinics/2019/e1205Clinics; Vol. 74 (2019); e1205Clinics; v. 74 (2019); e1205Clinics; Vol. 74 (2019); e12051980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/164113/157549https://www.revistas.usp.br/clinics/article/view/164113/157550Copyright (c) 2019 Clinicsinfo:eu-repo/semantics/openAccessFujita, Lívia Grimaldi AbudPalhares, Heloísa Marcelina da CunhaSilva, Adriana Paula daTomé, Janaíne MachadoBorges, Maria de Fátima2019-11-14T18:43:10Zoai:revistas.usp.br:article/164113Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2019-11-14T18:43:10Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Clinical and Laboratory Parameters of GonadotropinReleasing Hormone Analog Treatment Effectiveness in Children with Precocious Puberty
title Clinical and Laboratory Parameters of GonadotropinReleasing Hormone Analog Treatment Effectiveness in Children with Precocious Puberty
spellingShingle Clinical and Laboratory Parameters of GonadotropinReleasing Hormone Analog Treatment Effectiveness in Children with Precocious Puberty
Fujita, Lívia Grimaldi Abud
Gonadotropin-Releasing Hormone
Puberty
Therapeutics
Luteinizing Hormone
Follicle Stimulating Hormone
Estradiol
Growth
title_short Clinical and Laboratory Parameters of GonadotropinReleasing Hormone Analog Treatment Effectiveness in Children with Precocious Puberty
title_full Clinical and Laboratory Parameters of GonadotropinReleasing Hormone Analog Treatment Effectiveness in Children with Precocious Puberty
title_fullStr Clinical and Laboratory Parameters of GonadotropinReleasing Hormone Analog Treatment Effectiveness in Children with Precocious Puberty
title_full_unstemmed Clinical and Laboratory Parameters of GonadotropinReleasing Hormone Analog Treatment Effectiveness in Children with Precocious Puberty
title_sort Clinical and Laboratory Parameters of GonadotropinReleasing Hormone Analog Treatment Effectiveness in Children with Precocious Puberty
author Fujita, Lívia Grimaldi Abud
author_facet Fujita, Lívia Grimaldi Abud
Palhares, Heloísa Marcelina da Cunha
Silva, Adriana Paula da
Tomé, Janaíne Machado
Borges, Maria de Fátima
author_role author
author2 Palhares, Heloísa Marcelina da Cunha
Silva, Adriana Paula da
Tomé, Janaíne Machado
Borges, Maria de Fátima
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Fujita, Lívia Grimaldi Abud
Palhares, Heloísa Marcelina da Cunha
Silva, Adriana Paula da
Tomé, Janaíne Machado
Borges, Maria de Fátima
dc.subject.por.fl_str_mv Gonadotropin-Releasing Hormone
Puberty
Therapeutics
Luteinizing Hormone
Follicle Stimulating Hormone
Estradiol
Growth
topic Gonadotropin-Releasing Hormone
Puberty
Therapeutics
Luteinizing Hormone
Follicle Stimulating Hormone
Estradiol
Growth
description OBJECTIVE: There are no doubts about the clinical benefits of treatment with GnRH analogs for patients diagnosed with central precocious puberty (CPP). However, laboratory monitoring of CPP is still a matter of considerable controversy in the literature. Therefore, the main objective of this study was to evaluate the cut-off values of stimulated LH that determine gonadotrophic suppression. METHODS: Twenty-four girls, on treatment with leuprorelin acetate (LA) at 3.75 mg IM every 28 days, were studied. The clinical parameters used to indicate clinical effectiveness were regression or maintenance of sexual characteristics according to the Tanner stage, growth velocity reduction, reduction or maintenance of the difference between bone age and chronological age and maintenance or improvement of the final height prediction. For the laboratory effectiveness test, basal estradiol, LH, and FSH levels were collected before and 1 and 2 h after the administration of 3.75 mg LA. RESULTS: Eleven girls showed improvement in all clinical parameters, and their effectiveness tests were compared to those of the other patients to calculate the cut-off values, which were p3.64 IU/L (p=0.004*) for LH after 1 h and p6.10 IU/L (po0.001*) for LH after 2 h. CONCLUSION: The LH response after the LA stimulation test, associated with clinical data and within a context of CPP, constitutes a reliable and feasible resource and can assist in monitoring the effectiveness of treatment.
publishDate 2019
dc.date.none.fl_str_mv 2019-11-14
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/164113
10.6061/clinics/2019/e1205
url https://www.revistas.usp.br/clinics/article/view/164113
identifier_str_mv 10.6061/clinics/2019/e1205
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/164113/157549
https://www.revistas.usp.br/clinics/article/view/164113/157550
dc.rights.driver.fl_str_mv Copyright (c) 2019 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2019 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/xml
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 74 (2019); e1205
Clinics; v. 74 (2019); e1205
Clinics; Vol. 74 (2019); e1205
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222764648366080